Icosavax is a biopharmaceutical company utilizing its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Co.'s pipeline includes vaccine candidates targeting some of viral causes of pneumonia. Co.'s vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus, and IVX-241, a vaccine candidate designed to target human metapneumovirus. Co. is developing additional vaccine candidates to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults. The ICVX stock yearly return is shown above.
The yearly return on the ICVX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ICVX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|